Cardio‐Oncology/Onco‐Cardiology

Clinical Cardiology - Tập 33 Số 12 - Trang 733-737 - 2010
R Hong1, Takeshi Iimura1, Kenneth Sumida1, Robert M Eager1
1Internal Medicine Residency Program, The Queen's Medical Center, Honolulu, Hawaii

Tóm tắt

AbstractAn understanding of onco‐cardiology or cardio‐oncology is critical for the effective care of cancer patients. Virtually all antineoplastic agents are associated with cardiotoxicity, which can be divided into 5 categories: direct cytotoxic effects of chemotherapy and associated cardiac systolic dysfunction, cardiac ischemia, arrhythmias, pericarditis, and chemotherapy‐induced repolarization abnormalities. Radiation therapy can also lead to coronary artery disease and fibrotic changes to the valves, pericardium, and myocardium. All patients being considered for chemotherapy, especially those who have prior cardiac history, should undergo detailed cardiovascular evaluation to optimize the treatment. Serial assessment of left ventricular systolic function and cardiac biomarkers might also be considered in selected patient populations. Cardiotoxic effects of chemotherapy might be decreased by the concurrent use of angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, or beta‐blockers. Antiplatelet or anticoagulation therapy might be considered in patients with a potential hypercoagulable state associated with chemotherapy or cancer. Open dialogue between both cardiologists and oncologists will be required for optimal patient care. Copyright © 2010 Wiley Periodicals, Inc.The authors have no funding, financial relationships, or conflicts of interest to disclose.

Từ khóa


Tài liệu tham khảo

10.1016/j.jacc.2009.02.050

10.1002/cncr.11407

10.1200/JCO.2002.20.5.1215

Giordano SH, 2002, A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one‐ or three‐ hour‐ infusion paclitaxel in patients with metastatic breast cancer, Clin Cancer Res, 8, 3360

van Dalen EC, 2005, Cardioprotective interventions for cancer patients receiving anthracyclines, Cochrane Database Syst Rev, CD003917

10.1200/JCO.2008.17.2627

10.1016/j.ejca.2003.12.006

10.1016/j.cardfail.2009.04.011

10.1200/JCO.2005.13.300

10.1016/S0025-6196(11)60896-3

10.1182/blood-2007-01-070144

10.1002/cncr.23460

10.1016/S0140-6736(07)61865-0

10.1182/blood-2008-11-186817

10.1001/archinte.1981.00340060066015

10.1378/chest.99.3.557

10.1200/JCO.2005.05.098

10.1093/annonc/mdf108

10.3747/co.v17i1.437

10.1200/JCO.1989.7.4.509

Tsibiribi P, 2006, Cardiotoxicity of 5‐fluorouracil in 1350 patients with no prior history of heart disease, Bull Cancer, 93, E27

10.1177/030089168206800609

Schwarzer S, 1991, Non‐Q‐wave myocardial infarction associated with bleomycin and etoposide chemotherapy, Eur Heart J, 12, 748

10.1253/jcj.60.185

Schecter JP, 1975, Myocardial infarction in a 27‐year‐old woman: possible complication of treatment with VP‐16‐213 (NSC‐141540), mediastinal irradiation, or both, Cancer Chemother Rep, 59, 887

10.1159/000225128

10.1093/jnci/djk029

Subar M, 1986, Apparent myocardial ischemia associated with vinblastine administration, Cancer Treat Rep, 70, 690

10.1093/jnci/djm086

10.1056/NEJMoa060655

Arbuck SG, 1993, A reassessment of cardiac toxicity associated with Taxol, J Natl Cancer Inst Monogr, 117

10.1200/JCO.1989.7.1.7

10.1200/JCO.2001.19.18.3852

McLellan RA, 1996, Fluoroquinolone antibiotics inhibit cytochrome P450‐mediated microsomal drug metabolism in rat and human, Drug Metab Dispos, 24, 1134

10.1023/A:1006938908284

10.1016/0145-2126(94)00123-R

10.1038/sj.leu.2405062

10.1200/JCO.2006.07.9525

10.1200/JCO.2006.10.2434

10.1016/0002-9343(81)90574-X

10.1016/S0046-8177(96)90447-5

10.1002/1097-0142(197606)37:6<2813::AID-CNCR2820370637>3.0.CO;2-S

10.1016/j.ahj.2004.12.026

Gyenes G, 1997, Detection of radiation‐induced myocardial damage by technetium‐99m sestamibi scintigraphy, Eur J Nucl Med, 24, 286

10.1200/JCO.1994.12.3.447

10.1093/jnci/djk064

10.1002/cncr.10854

10.1016/0002-9343(87)90212-9

10.1159/000227621

10.1016/j.ejca.2006.08.002

Steinherz LJ, 1992, Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group, Pediatrics, 89, 942, 10.1542/peds.89.5.942

10.1200/JCO.2005.04.9551

10.1161/01.CIR.0000130926.51766.CC

10.1046/j.1365-2796.2002.00951.x

10.1161/CIRCULATIONAHA.106.635144

10.1016/j.jacc.2006.07.052

10.1002/cncr.21478

10.1161/CIRCULATIONAHA.109.895771

Thông tin
Thông tin xuất bản

Clinical Cardiology

Tập 33 Số 12

733-737

Thông tin tác giả